Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > AlphaRx Appoints Leading Infectious Disease Specialist to Its Scientific Advisory Board

Abstract:
AlphaRx Inc. is pleased to announce the appointment of Dr. Donald Low to its Scientific Advisory Board (SAB), effective immediately. With more than 30 years of experience, Dr. Low is recognized world-wide as an authority in the area of emerging infectious diseases.

AlphaRx Appoints Leading Infectious Disease Specialist to Its Scientific Advisory Board

MARKHAM, ON, Canada | Posted on September 17th, 2008

Dr. Low is currently Head the Division of Microbiology, Department of Laboratory Medicine and Pathobiology at the in Toronto, Ontario. He is also Chief of University Health Network and Mount Sinai Hospital Department of Microbiology, as well as Professor for the Departments of Microbiology and Medicine at the . In addition, Dr. Low is Medical Director of the Public Health Laboratories for the Ontario Ministry of Health and Long-Term Care.

Dr. Low brings with him years of research experience in infectious diseases, particularly in new drug investigation, clinical trials design and implementation. The Scientific Advisory Board (SAB) will be instrumental in implementing AlphaRx's goal of advancing its lead pharmaceutical product Zysolin(TM) through clinical development.

About Zysolin(TM)

Zysolin(TM) is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin(TM) improves the intracellular activity of Tobramycin - in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin(TM), Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin(TM) will have an attractive safety, tolerability and efficacy profile when compared to injectable Tobramycin.

####

About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

For more information, please click here

Contacts:
Agora Investor Relations Corp.

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Future electronic components to be printed like newspapers July 20th, 2018

The relationship between charge density waves and superconductivity? It's complicated July 19th, 2018

Sirrus's Issued Patent Portfolio Continues To Accelerate July 18th, 2018

FEFU scientists reported on toxicity of carbon and silicon nanotubes and carbon nanofibers: Nanoparticles with a wide range of applying, including medicine, damage cells of microalgae Heterosigma akashivo badly. July 18th, 2018

Nanomedicine

Nano-kirigami: 'Paper-cut' provides model for 3D intelligent nanofabrication July 13th, 2018

UMBC researchers develop nanoparticles to reduce internal bleeding caused by blast trauma July 13th, 2018

Researchers identify cost-cutting option in treating nail fungus with nanotechnology: GW researcher Adam Friedman, M.D., studied the potential use of nitric oxide-releasing nanoparticles to improve onychomycosis treatment July 11th, 2018

New sensor technology enables super-sensitive live monitoring of human biomolecules July 3rd, 2018

Announcements

Future electronic components to be printed like newspapers July 20th, 2018

The relationship between charge density waves and superconductivity? It's complicated July 19th, 2018

Sirrus's Issued Patent Portfolio Continues To Accelerate July 18th, 2018

FEFU scientists reported on toxicity of carbon and silicon nanotubes and carbon nanofibers: Nanoparticles with a wide range of applying, including medicine, damage cells of microalgae Heterosigma akashivo badly. July 18th, 2018

Appointments/Promotions/New hires/Resignations/Deaths

Jim Barnhart Joins Nanometrics as Senior Vice President of Operations March 15th, 2018

Jonathan Chou to Join Nanometrics as Chief Financial Officer February 26th, 2018

Ocean Optics Grows Sales Organization with Executive Appointments: Henry Langston promoted, Christine Stannard joins spectral sensing product developer December 23rd, 2017

Emmanuel Sabonnadiere is Letiís New CEO November 28th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project